Insulin Glargine (Lantus, Toujeo) Market Analysis: Impact Of Biosimilars And Patent Expiry On Global Market Dynamics
- Published: Oct, 2025
- Report ID: GVR-MT-100472
- Format: PDF/Excel databook
- No. of Pages/Datapoints: 120
- Report Coverage: 2024 - 2030
Table of Contents
Chapter 1. Methodology and Scope
1.1. Market Segmentation & Scope
1.2. Segment Definitions
1.3. Estimates and Forecast Timeline
1.4. Research Methodology
1.5. Information Procurement
1.5.1. Purchased Database
1.5.2. GVR’s Internal Database
1.5.3. Secondary Sources
1.5.4. Primary Research
1.6. Information Analysis
1.6.1. Data Analysis Models
1.7. Market Formulation & Data Visualization
1.8. Model Details
1.8.1. Commodity Flow Analysis
1.9. List of Secondary Sources
1.10. Objectives
Chapter 2. Executive Summary
2.1. Market Snapshot
2.2. Segment Snapshot
2.3. Competitive Landscape Snapshot
Chapter 3. Insulin Glargine (Lantus, Toujeo) Market Variables, Trends, & Scope
3.1. Market Lineage Outlook
3.2. Market Dynamics
3.2.1. Market Driver Analysis
3.2.2. Market Restraint Analysis
3.3. Business Environment Analysis
3.3.1. Industry Analysis - Porter’s Five Forces Analysis
3.3.1.1. Supplier Power
3.3.1.2. Buyer Power
3.3.1.3. Substitution Threat
3.3.1.4. Threat of New Entrants
3.3.1.5. Competitive Rivalry
3.3.2. PESTLE Analysis
3.3.3. Pipeline Analysis
3.3.4. Pricing Analysis
Chapter 4. Insulin Glargine (Lantus, Toujeo) Market: Product Business Analysis
4.1. Product Market Share, 2024 & 2033
4.2. Product Segment Dashboard
4.3. Market Size & Forecasts and Trend Analysis, by Product, 2021 to 2033 (USD Million)
4.4. Lantus (Insulin Glargine U-100)
4.4.1. Lantus (Insulin Glargine U-100) Market, 2021 - 2033 (USD Million)
4.5. Biosimilars
4.5.1. Biosimilars Market, 2021 - 2033 (USD Million)
Chapter 5. Insulin Glargine (Lantus, Toujeo) Market: Application Business Analysis
5.1. Application Market Share, 2024 & 2033
5.2. Application Segment Dashboard
5.3. Market Size & Forecasts and Trend Analysis, by Application, 2021 to 2033 (USD Million)
5.4. Type 1 Diabetes
5.4.1. Type 1 Diabetes Market, 2021 - 2033 (USD Million)
5.5. Type 2 Diabetes
5.5.1. Type 2 Diabetes Market, 2021 - 2033 (USD Million)
Chapter 6. Insulin Glargine (Lantus, Toujeo) Market: Distribution Channel Business Analysis
6.1. Distribution Channel Market Share, 2024 & 2033
6.2. Distribution Channel Segment Dashboard
6.3. Market Size & Forecasts and Trend Analysis, by Distribution Channel, 2021 to 2033 (USD Million)
6.4. Hospital Pharmacies
6.4.1. Hospital Pharmacies Market, 2021 - 2033 (USD Million)
6.5. Retail Pharmacies
6.5.1. Retail Pharmacies Market, 2021 - 2033 (USD Million)
6.6. Online Pharmacies
6.6.1. Online Pharmacies Market, 2021 - 2033 (USD Million)
Chapter 7. Insulin Glargine (Lantus, Toujeo) Market: Regional Estimates & Trend Analysis
7.1. Regional Market Share Analysis, 2024 & 2033
7.2. Regional Market Dashboard
7.3. Market Size & Forecasts Trend Analysis, 2021 to 2033:
7.4. North America
7.5. Europe
7.6. Asia Pacific
7.7. Latin America
7.8. Middle East and Africa
Chapter 8. Competitive Landscape
8.1. Company Profile
8.1.1. Sanofi
8.1.1.1. Overview
8.1.1.2. Financial Performance
8.1.1.3. Strategic Mapping
8.1.2. Eli Lilly and Company
8.1.2.1. Overview
8.1.2.2. Financial Performance
8.1.2.3. Product Benchmarking
8.1.2.4. Strategic Mapping
8.2. Biosimilar Manufacturers
8.2.1. Biocon Biologics / Viatris
8.2.1.1. Overview
8.2.1.2. Financial Performance
8.2.1.3. Product Benchmarking
8.2.1.4. Strategic Mapping
8.2.2. Wockhardt
8.2.2.1. Overview
8.2.2.2. Financial Performance
8.2.2.3. Product Benchmarking
8.2.2.4. Strategic Mapping
8.2.3. Braun SE
8.2.3.1. Overview
8.2.3.2. Financial Performance
8.2.3.3. Product Benchmarking
8.2.3.4. Strategic Mapping
List of Tables
Table 1 List of secondary sources
Table 2 List of abbreviations
Table 3 Global Insulin Glargine (Lantus, Toujeo) market, by Region, 2021 - 2033 (USD Million)
Table 4 North America Insulin Glargine (Lantus, Toujeo) market, by Product, 2021 - 2033 (USD Million)
Table 5 North America Insulin Glargine (Lantus, Toujeo) market, by Application, 2021 - 2033 (USD Million)
Table 6 North America Insulin Glargine (Lantus, Toujeo) market, by Distribution Channel, 2021 - 2033 (USD Million)
Table 7 Europe Insulin Glargine (Lantus, Toujeo) market, by Product, 2021 - 2033 (USD Million)
Table 8 Europe Insulin Glargine (Lantus, Toujeo) market, by Application, 2021 - 2033 (USD Million)
Table 9 Europe Insulin Glargine (Lantus, Toujeo) market, by Distribution Channel, 2021 - 2033 (USD Million)
Table 10 Asia Pacific Insulin Glargine (Lantus, Toujeo) market, by Product, 2021 - 2033 (USD Million)
Table 11 Asia Pacific Insulin Glargine (Lantus, Toujeo) market, by Application, 2021 - 2033 (USD Million)
Table 12 Asia Pacific Insulin Glargine (Lantus, Toujeo) market, by Distribution Channel, 2021 - 2033 (USD Million)
Table 13 Latin America Insulin Glargine (Lantus, Toujeo) market, by Product, 2021 - 2033 (USD Million)
Table 14 Latin America Insulin Glargine (Lantus, Toujeo) market, by Application, 2021 - 2033 (USD Million)
Table 15 Latin America Insulin Glargine (Lantus, Toujeo) market, by Distribution Channel, 2021 - 2033 (USD Million)
Table 16 Middle East & Africa Insulin Glargine (Lantus, Toujeo) market, by Product, 2021 - 2033 (USD Million)
Table 17 Middle East & Africa Insulin Glargine (Lantus, Toujeo) market, by Application, 2021 - 2033 (USD Million)
Table 18 Middle East & Africa Insulin Glargine (Lantus, Toujeo) market, by Distribution Channel, 2021 - 2033 (USD Million)
List of Figures
Fig. 1 Insulin Glargine (Lantus, Toujeo) market segmentation
Fig. 2 Market research process
Fig. 3 Data triangulation techniques
Fig. 4 Primary research pattern
Fig. 5 Market research approaches
Fig. 6 Value-chain-based sizing & forecasting
Fig. 7 Market formulation & validation
Fig. 8 Market snapshot
Fig. 9 Indication outlook (USD Million)
Fig. 10 Competitive landscape
Fig. 11 Insulin Glargine (Lantus, Toujeo) market dynamics
Fig. 12 Insulin Glargine (Lantus, Toujeo) market: Porter’s five forces analysis
Fig. 13 Insulin Glargine (Lantus, Toujeo) market: PESTLE analysis
Fig. 14 Product market, 2021 - 2033 (USD Million)
Fig. 15 Lantus (Insulin Glargine U-100) market, 2021 - 2033 (USD Million)
Fig. 16 Toujeo (Insulin Glargine U-300) market, 2021 - 2033 (USD Million)
Fig. 17 Biosimilars market, 2021 - 2033 (USD Million)
Fig. 18 Application market, 2021 - 2033 (USD Million)
Fig. 19 Type 1 Diabetes market, 2021 - 2033 (USD Million)
Fig. 20 Type 2 Diabetes market, 2021 - 2033 (USD Million)
Fig. 21 Distribution Channel market, 2021 - 2033 (USD Million)
Fig. 22 Hospital Pharmacies market, 2021 - 2033 (USD Million)
Fig. 23 Retail Pharmacies market, 2021 - 2033 (USD Million)
Fig. 24 Online Pharmacies market, 2021 - 2033 (USD Million)
Fig. 25 Insulin Glargine (Lantus, Toujeo) market revenue, by region
Fig. 26 Regional marketplace: Key takeaways
Fig. 27 North America Insulin Glargine (Lantus, Toujeo) market, 2021 - 2033 (USD Million)
Fig. 28 Europe Insulin Glargine (Lantus, Toujeo) market, 2021 - 2033 (USD Million)
Fig. 29 Asia Pacific Insulin Glargine (Lantus, Toujeo) market, 2021 - 2033 (USD Million)
Fig. 30 Latin America Insulin Glargine (Lantus, Toujeo) market, 2021 - 2033 (USD Million)
Fig. 31 MEA Insulin Glargine (Lantus, Toujeo) market, 2021 - 2033 (USD Million)
Fig. 32 Company categorization
Fig. 33 Company market position analysis
Fig. 34 Strategic framework
GET A FREE SAMPLE
This FREE sample includes market data points, ranging from trend analyses to market estimates & forecasts. See for yourself.
NEED A CUSTOM REPORT?
We can customize every report - free of charge - including purchasing stand-alone sections or country-level reports, as well as offer affordable discounts for start-ups & universities.
Contact us now to get our best pricing.
ESOMAR certified & member
ISO Certified
We are GDPR and CCPA compliant! Your transaction & personal information is safe and secure. For more details, please read our privacy policy.